Max India Limited (MAXIND) has launched the SCALE initiative in collaboration with the Max Institute of Healthcare Management (MIHM) at the Indian School of Business (ISB) and Antara Senior Care to advance senior-care research. The SCALE initiative aims to bridge research and industry experience to develop scalable solutions for India’s rapidly growing senior population.

Addressing the Gap in Senior-Care Research

India is witnessing an increasing demand for senior care that is accessible, appropriate, and sustainable. However, these learnings remain fragmented. The SCALE Initiative seeks to address this gap by generating evidence and translating it into insights that can assist industry stakeholders and policymakers to make informed decisions.

Focus Areas of the SCALE Initiative

The initiative will focus on consumer behavior, workforce participation, social inclusion, operating and care delivery models, and technology adoption. Antara Senior Care, as the founding industry partner, is supporting SCALE’s engagement with the senior care sector.

Future of Senior Care in India

SCALE will bring together researchers, senior care industry stakeholders, and clinicians to examine the evolving care needs of seniors and identify priority action areas. The initiative aims to build an industry-level evidence base to help organizations innovate, respond to evolving consumer needs, make informed business and investment decisions, strengthen workforce strategies, and scale effective approaches.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Max India Limited

Max India Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Max moves sideways over three months, with neither buyers nor sellers taking control. Industry-leading margins of 55.4% reflect exceptional pricing power and operational efficiency. 5 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock gains 6.6% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Price climbs recently despite -1.8% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Max India Limited.

Zydus Lifesciences Limited (NSE: ZYDUSLIFE) has unveiled new post hoc analysis from the pivotal Phase 3 EPICS-III trial of saroglitazar, showing greater biochemical response compared to placebo across geographic subgroups in patients with primary biliary cholangitis (PBC). The findings were presented at the American College of Gastroenterology (ACG) 2026 Annual Meeting.

Greater Biochemical Response in U.S. Subgroup

Numerically higher biochemical response treatment difference was observed in the U.S. subgroup relative to the non-U.S. subgroup (∆ 60.7% vs. ∆ 41.6%) in patients with PBC. These results build on the clinical profile of saroglitazar in patients with PBC who have inadequate response or intolerance to ursodeoxycholic acid (UDCA).

EPIC-III Trial Overview

The EPICS-III trial is a multicenter, randomized, double-blind, placebo-controlled, seamless Phase 2(b)/3 trial evaluating the efficacy and safety of saroglitazar in patients with PBC who had an inadequate response to or intolerance of UDCA. The trial included nearly thirty percent of patients from the U.S. and composite biochemical response rates were greater with saroglitazar than placebo in both U.S. (60.7% vs. 0%) and non-U.S. subgroup regions (55.1% vs. 13.5%). Saroglitazar was generally well tolerated, with adverse events generally balanced between saroglitazar-treated and placebo-treated patients.

As a result, Zydus Therapeutics plans to launch saroglitazar in the United States by March 2027 if approved by the FDA. These findings provide additional insight into the Phase 3 EPICS-III results and the biochemical responses observed among patients enrolled in different geographic regions.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Zydus Lifesciences Limited

Zydus Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Zydus holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.68 signals undervaluation relative to growth. It is a potential re-rating candidate. The business compounds revenue at 16.5% and profits at 37.0% CAGR. That is strong double-digit growth on both counts. The stock trades at 75% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Revenue grows at 16.5% and profits at 37.0%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Zydus Lifesciences Limited.

Wanbury Limited, a pharmaceutical company with a global API presence and domestic branded formulations portfolio, announced the launch of its berrysoft™ baby product range across multiple states in India through its subsidiary Wanbury Skin Health Limited. The launch marks a strategic entry into the paediatric dermatology segment.

Strategic Expansion

The berrysoft™ baby range has been developed to address everyday baby skincare and hygiene needs. The product portfolio includes Gentle Bathing Bar, Gentle Body Wash, Foam Shampoo, Syndet Handwash, Moisturising Lotion, Diaper Rash Cream, and Moisturising Cream in the pipeline. This initiative reflects Wanbury Limited’s focus on expanding its overall healthcare portfolio through its various subsidiaries.

Market Presence

Wanbury Skin Health Limited has received GST registration in five states including Maharashtra, Delhi, and Karnataka, with three more in pipeline. The company also has received CFA Drug Licenses in Mumbai, Jaipur, Patna, and Ambala, with four more in pipeline. This multi-state launch marks an important milestone in Wanbury Limited’s growth strategy, combining portfolio diversification with deeper engagement across its existing healthcare professional network.

Future Prospects

Wanbury Limited aims to leverage established market relationships to drive growth in complementary product categories and strengthen its presence across relevant healthcare segments. The company will continue to explore opportunities to broaden its product portfolio and strengthen its presence across relevant healthcare categories.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Wanbury Limited

Wanbury Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Wanbury drops 34.0% over three months and trades near its 52-week lows. Thin margins at 8.6% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. RSI stands at 31, well into oversold territory. Yet sellers still dominated on 20 of recent sessions versus 10 for buyers, so the pressure has not fully lifted. Revenue grows at 8.9% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Wanbury Limited.